BIORCHESTRA is proud to announce that we have signed an exclusive research and option agreement of up to $861M with a global biopharmaceutical company to leverage BIORCHESTRA’s Targeting Technology Platform (BDDS™) and develop nucleic acid therapies for the treatment of neurological disorders and against multiple targets.